• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » VGX-100 identified as potential therapy for improving corneal graft survival

VGX-100 identified as potential therapy for improving corneal graft survival

January 30, 2012
CenterWatch Staff

Circadian Technologies has published data in Investigative Ophthalmology & Visual Science (IOVS) showing that VEGF-C expression is markedly up-regulated in corneal graft rejection. The data also showed that VEGF-C blockade, through administration of Circadian's lead development candidate VGX-100, a human antibody against VEGF-C, significantly improved corneal graft survival in an animal model. The data indicates a new therapeutic opportunity for VGX-100 to improve corneal graft survival.

While most corneal grafts take very well, it is estimated that between 10% and 30% of grafts will be rejected within six to 12 months, particularly in "at-risk" patients who have a highly vascularized eye bed or in whom a graft has previously failed. The study, which was led by Professor Reza Dana and Dr Amir R. Hajrasouliha of the Schepens Eye Research Institute, Harvard Medical School department of ophthalmology, showed that VEGF-C was markedly up-regulated in rejected corneas and that administration of VGX-100 was able to significantly improve corneal graft survival.

"Corneal grafting can have enormously positive results for patients who may otherwise become blind. While grafting success has improved significantly over the past 20 years, there are still a large number of grafts which continue to fail,” said Dana, senior author of the study. “Our findings demonstrating that VEGF-C is up-regulated in graft failure and that blockade of VEGF-C could significantly improve graft survival and identify VEGF-C blockade as an exciting new therapeutic possibility for improving corneal graft survival."

Cicadian Technologies is currently undertaking additional preclinical studies with VGX-100 in the corneal grafting setting with the aim to commence clinical trials in 2013.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing